China NMPA approves Dizal's sunvozertinib to treat locally advanced or metastatic NSCLC with EGFR Exon20ins mutations: Shanghai Thursday, August 24, 2023, 18:00 Hrs [IST] Dizal, a ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by blinded independent central review in newly diagnosed EGFR exon 20 insertion ...

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.

Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...

One of the more competitive targets in lung cancer is a certain mutation that has eluded many available targeted therapies. A drug developed by Dizal Pharmaceutical has received FDA approval for ...

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug ...

ArriVent BioPharma, Inc. has announced promising findings from its clinical studies involving firmonertinib, an EGFR inhibitor promising strong anti-tumor activity against non-small cell lung cancer ...

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...